The molecular test detects a form of herpes virus that can infect newborns and cause deafness.
In the firm's first-ever earnings call, new CEO Jack Kenny said the firm will invest more in R&D to revamp its aging portfolio.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.
The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.
The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.
The firm attributes the positive results to efforts to strengthen its US diagnostics business and stabilize its core diagnostics product families of H. pylori and food testing.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.